RxDoctor Payments Data

Joseph Samyn, MD

Cardiovascular Disease · Crown Point, INNPI 1366449373

Payments from drug & device makers

$995in general payments, 2019–2025

Across 49 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$228
  • Johnson & Johnson$201
  • Abbott$194
  • Abiomed$81
  • Baxter Healthcare$51
  • Boehringer Ingelheim$47
  • plus $194 from 7 others

What the payments were for

  • Food & beverage$94495%
  • Other$515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$995 in reported general payments places this provider in the 30th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$244,527
Medicare patients
1,847
Services billed
3,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban486$578,495
EntrestoSacubitril/Valsartan205$289,188
XareltoRivaroxaban210$260,855
BrilintaTicagrelor30$30,699
Repatha SureclickEvolocumab23$24,387
JardianceEmpagliflozin22$23,146
FarxigaDapagliflozin Propanediol15$17,769
Praluent PenAlirocumab16$15,736
Atorvastatin Calcium1,041$7,779
Metoprolol Succinate692$7,544
Nitroglycerin PatchNitroglycerin169$6,760
ClopidogrelClopidogrel Bisulfate417$4,147
Diltiazem 24hr Er (Cd)Diltiazem Hcl97$3,890
Losartan Potassium507$3,870
Carvedilol410$3,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$578,495486 claims
NovartisEntresto$228$289,188205 claims
Johnson & JohnsonXarelto$201$260,855210 claims
Boehringer IngelheimJardiance$47$23,14622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Crown Point

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →